MCL promotes radiosensitivity in p53-deficient non-small cell lung cancer (NSCLC) by inhibiting the HIF-1α pathway, thereby promoting its degradation (Kong et al., 2020). The gene discussed is TP53; the disease is non-small cell lung carcinoma.